Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dasatinib in advanced HER-2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088

Dasatinib in advanced HER-2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. Journal of Clinical Oncology. 2009; A1011.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.